Factor II Prothrombin – G20210A mutation
Private Factor II Prothrombin G20210A mutation test in London for £198, with specialist genetic results expected in approximately 5 business days.
Turnaround time
5 business days
Biomarkers count
1
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Factor II Prothrombin – G20210A mutation
The Factor II Prothrombin – G20210A mutation test is a genetic thrombophilia test used to detect the common G20210A variant within the Prothrombin, or F2, gene.
The test contains 1 biomarker: Factor II Prothrombin – G20210A mutation.
Prothrombin is a clotting protein produced by the liver.
During coagulation, Prothrombin is converted into Thrombin, an enzyme that plays a central role in formation of a stable blood clot.
The G20210A variant is associated with increased Prothrombin production and an increased tendency towards venous thromboembolism.
People carrying one copy of the variant are described as heterozygous.
A much smaller number inherit two copies.
Having the variant does not mean that a blood clot will definitely occur.
Many carriers never experience thrombosis.
Risk becomes more important when the genetic tendency combines with acquired risk factors such as surgery, immobilisation, pregnancy, oestrogen-containing medication, obesity or another inherited thrombophilia.
The variant is principally associated with deep vein thrombosis and pulmonary embolism, rather than being a universal explanation for every type of blood clot.
Because the test examines DNA, the genetic result remains the same throughout life and usually only needs to be performed once.
Anticoagulant medicines do not change the genetic sequence and therefore do not produce a false-negative mutation result.
What Does the Factor II Prothrombin – G20210A mutation Test Check?
This test measures 1 biomarker.
Factor II Prothrombin – G20210A mutation
Detects the common inherited G20210A variant in the F2 gene associated with increased Prothrombin levels and increased susceptibility to venous thrombosis.
Who May Benefit From the Factor II Prothrombin – G20210A mutation Test?
Genetic testing may be appropriate when personal or family history suggests an inherited tendency towards thrombosis.
People with an unexplained deep vein thrombosis - Inherited thrombophilia may be considered when a clot occurs without a major temporary trigger.
People with an unexplained pulmonary embolism - The Prothrombin variant can increase venous thromboembolism risk.
People who develop thrombosis at a relatively young age - Earlier events can make inherited risk factors more relevant.
People with a strong family history of venous thrombosis - The variant can run within families.
People with recurrent venous blood clots - More detailed thrombophilia assessment may occasionally be appropriate.
Women undergoing selected recurrent pregnancy-loss assessment - Genetic thrombophilia testing may be considered according to specialist guidance and the complete history.
People with another known inherited thrombophilia - Combined risk factors can affect overall thrombosis susceptibility.
People specifically advised to obtain F2 G20210A genetic testing - Testing should ideally answer a defined clinical question.
How to Prepare
Do not stop anticoagulant treatment for this genetic test.
Because the mutation is inherited and permanent, medication does not alter whether the variant is present.
Symptoms and Reasons to Consider the Factor II Prothrombin – G20210A mutation Test
The mutation itself causes no symptoms. Symptoms occur only if a clinically significant blood clot develops.
Pain and swelling affecting one leg - These can occur with deep vein thrombosis.
Warmth or redness of one leg - DVT can produce local inflammatory changes.
Sudden unexplained breathlessness - Pulmonary embolism can cause acute respiratory symptoms.
Sharp chest pain that worsens when breathing - This can occur with pulmonary embolism.
Coughing blood - Haemoptysis can occur with pulmonary embolism and requires urgent assessment.
A previous unexplained DVT or pulmonary embolism - Genetic testing may help identify an inherited contributor.
Multiple relatives with venous blood clots - Familial clustering increases the relevance of inherited thrombophilia assessment.
A clot following a relatively minor trigger - Genetic predisposition may be considered where thrombosis seems disproportionate to the provoking factor.
The genetic variant itself does not require emergency treatment.
However, new symptoms of DVT or pulmonary embolism require urgent medical assessment and should not wait for a genetic blood-test result.
How to Book Your Factor II Prothrombin – G20210A mutation Test
Booking your Prothrombin G20210A genetic test with London Blood Tests is straightforward.
Choose the Factor II Prothrombin – G20210A mutation
Select the individual inherited thrombophilia genetic test.
Select your sample collection option
Choose an in-clinic blood draw or professional home or hotel phlebotomy.
Attend your appointment
A trained professional collects the required EDTA blood sample and relevant clinical history is documented.
Laboratory analysis
Your DNA is analysed for the Factor II Prothrombin G20210A variant.
Receive your results securely
Your authorised genetic report is delivered securely for discussion with a GP or haematologist where appropriate.
When Will I Receive My Results?
The current specialist laboratory turnaround is approximately 5 business days after your sample reaches the laboratory.
This is a molecular genetic test and requires DNA analysis rather than a routine clotting measurement.
The sample must be received, processed and analysed before the genetic result can be authorised.
Occasional repeat molecular analysis or specimen-quality concerns may extend the reporting period.
Understanding Your Results
A negative result means the common G20210A variant was not detected.
This reduces the likelihood that this particular inherited thrombophilia contributes to your risk but does not exclude other inherited or acquired causes of thrombosis.
A heterozygous positive result means one copy of the variant is present.
This is associated with an increased relative risk of venous thrombosis compared with people who do not carry the variant.
A homozygous result means two copies are present and is considerably less common.
The absolute risk of developing a clot depends on additional factors such as age, surgery, immobilisation, pregnancy, oestrogen therapy and other thrombophilias.
A positive genetic result does not automatically mean that lifelong anticoagulation is required.
Management should be based on the complete clinical risk profile.
Why Book With London Blood Tests?
Private Prothrombin mutation testing in London - Access targeted inherited thrombophilia analysis privately.
Permanent genetic result - The variant does not change over time.
Relevant to unexplained venous thrombosis - The mutation is an established inherited risk factor.
Useful in family risk assessment - Genetic information can provide context where thrombosis clusters within a family.
Not affected by anticoagulants - Medication does not alter the DNA sequence.
Specialist genetic analysis - Samples undergo dedicated molecular testing.
Secure reporting - Receive your authorised result securely.
Clear pricing - The Factor II Prothrombin G20210A mutation test costs £198.
Private Factor II Prothrombin – G20210A mutation Blood Test in London
London Blood Tests provides private Factor II Prothrombin G20210A genetic testing in London for people requiring investigation of inherited venous thrombosis risk.
The test costs £198 and measures one biomarker.
Results are expected approximately 5 business days after laboratory receipt.
A positive result identifies a risk factor rather than a prediction that a blood clot will definitely occur.